Treatment for multiple myeloma (MM)

Abstract

The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.

What is claimed is: 
     
       1. A method for treatment of multiple myeloma, said method comprising administering to a human patient in need dexamethasone and an antibody specific for CD38, said antibody comprising a variable heavy domain encoded by SEQ ID NO:11 and a variable light domain encoded by SEQ ID NO:12, wherein said antibody is administered at a dose of 16 mg/kg once weekly to significantly improve overall response of the human patient over human patients receiving 4 or 8 mg/kg once weekly or once every other week of said antibody in combination with dexamethasone. 
     
     
       2. The method according to  claim 1 , wherein said antibody is administered once weekly (q1w) over at least eight weeks. 
     
     
       3. The method according to  claim 1 , wherein said antibody is administered intravenously. 
     
     
       4. The method according to  claim 1 , wherein said antibody is administered intravenously over a period of two hours. 
     
     
       5. The method according to  claim 1 , wherein said antibody comprises an IgG1 Fc region. 
     
     
       6. The method according to  claim 1 , wherein the dexamethasone is dosed at 20 mg or 40 mg once weekly (q1W). 
     
     
       7. The method of  claim 1  wherein the patient has relapsed/refractory multiple myeloma in humans.